BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li J, Liu Z, Hu P, Wen Z, Cao Q, Zou X, Chen Y, Wang Y, Zhong J, Shen X, Demuth D, Fadeeva O, Xie L, Chen J, Qian J. Indicators of suboptimal response to anti-tumor necrosis factor therapy in patients from China with inflammatory bowel disease: results from the EXPLORE study. BMC Gastroenterol 2022;22:44. [PMID: 35120446 DOI: 10.1186/s12876-021-02074-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Park SH, Park SH. Personalized medicine in inflammatory bowel disease: Perspectives on Asia. J Gastroenterol Hepatol 2022. [PMID: 35726657 DOI: 10.1111/jgh.15919] [Reference Citation Analysis]
2 Yang WS, Wang JL, Wu W, Wang GF, Yan J, Liu Q, Wu XY, Zhou QT, Yang DH, Wang MW, Li ZP. Formyl peptide receptor 2 as a potential therapeutic target for inflammatory bowel disease. Acta Pharmacol Sin 2022. [PMID: 35840658 DOI: 10.1038/s41401-022-00944-0] [Reference Citation Analysis]
3 Pu D, Zhang Z, Feng B. Alterations and Potential Applications of Gut Microbiota in Biological Therapy for Inflammatory Bowel Diseases. Front Pharmacol 2022;13:906419. [DOI: 10.3389/fphar.2022.906419] [Reference Citation Analysis]